tirzepatide for depression Once-weekly subcutaneous tirzepatide was not associated with an increased risk of depression compared New weight-loss drugs linked to

They openly praise FDA warnings (for example, an FDA alert from July 29, 2025 about compound risks is cited in Novos press releases)

Absence of extensive clinical trials does not equate to harm or inefficacymany natural, essential nutrients and biomolecules lack commercial trial data but are safe and beneficial when used responsibly

What's worth your attention instead is what's actually inconsistent in the brand's own published materials - the guarantee-window and return-procedure conflicts covered above - since that's the kind of detail a complaint search often turns up after the fact anyway

Consultado el 2 de octubre de 2025: Informe de Posicionamiento Teraputico de tirzepatida (Mounjaro), AEMPS

High-dose Vitamin C IV therapy may be appropriate for individuals seeking additional immune support, particularly those experiencing frequent illness, prolonged fatigue, or increased inflammatory burden